Alvotech, Teva reach settlement with Regeneron over Eylea biosimilar AVT06 in U.S.

 According to the settlement agreement, the proposed biosimilar to Eylea® (aflibercept) can be marketed in the U.S., if approved by the FDA, in the fourth quarter of 2026, or earlier under certain circumstances

https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2025/Alvotech-and-Teva-Secure-U-S--Settlement-Date-for-AVT06-a-Proposed-Biosimilar-to-Eylea/default.aspx